FunPep Company Limited Logo

FunPep Company Limited

Biotech firm developing peptide-based therapeutics, cosmetics, and medical devices.

4881 | T

Overview

Corporate Details

ISIN(s):
JP3802640007
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ七丁目7−15
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

FunPep Company Limited is a clinical-stage biotechnology company that originated as a spin-out from Osaka University. The company specializes in the research and development of therapeutics based on its proprietary functional peptide and antibody-inducing peptide platform technologies. Its core business is creating novel peptide-based pharmaceutical products. FunPep's development pipeline includes candidates for various indications, such as an allergy vaccine and the functional peptide SR-0379 for intractable ulcers, which has advanced to late-stage clinical trials. The company's business scope also extends to the development of functional cosmetics and medical devices, leveraging the diverse applications of its core peptide technology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 08:30
Report Publication Announcement
確認書
Japanese 8.4 KB
2025-08-14 08:30
Interim Report
半期報告書-第13期(2025/01/01-2025/12/31)
Japanese 278.9 KB
2025-04-01 08:30
Post-Annual General Meeting Information
臨時報告書
Japanese 23.2 KB
2025-03-28 08:16
Registration Form
確認書
Japanese 8.5 KB
2025-03-28 08:15
Annual Report
有価証券報告書-第12期(2024/01/01-2024/12/31)
Japanese 1.6 MB
2025-03-28 08:15
Governance Information
内部統制報告書-第12期(2024/01/01-2024/12/31)
Japanese 23.6 KB
2025-02-21 07:30
Registration Form
有価証券届出書(組込方式)
Japanese 447.3 KB
2024-08-08 09:01
Report Publication Announcement
確認書
Japanese 8.4 KB
2024-08-08 09:00
Interim Report
半期報告書-第12期(2024/01/01-2024/12/31)
Japanese 283.1 KB
2024-08-08 03:00
Major Shareholding Notification
臨時報告書
Japanese 21.3 KB
2024-07-05 08:05
Registration Form
有価証券届出書(組込方式)
Japanese 391.3 KB
2024-05-13 08:00
Quarterly Report
確認書
Japanese 8.4 KB
2024-05-13 08:00
Quarterly Report
四半期報告書-第12期第1四半期(2024/01/01-2024/03/31)
Japanese 238.2 KB
2024-04-01 08:05
Post-Annual General Meeting Information
臨時報告書
Japanese 27.7 KB
2024-03-28 07:15
Registration Form
確認書
Japanese 8.5 KB

Automate Your Workflow. Get a real-time feed of all FunPep Company Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for FunPep Company Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for FunPep Company Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.